首页> 外文会议>Conference of the American^College^of^Veterinary^Internal^Medicine >MYCOBACTERIUM CELL WALL FRACTION (MCWF) AS AN AID IN THE TREATMENT OF CHEMOTHERAPY- INDUCED NEUTROPENIA IN DOGS
【24h】

MYCOBACTERIUM CELL WALL FRACTION (MCWF) AS AN AID IN THE TREATMENT OF CHEMOTHERAPY- INDUCED NEUTROPENIA IN DOGS

机译:分枝杆菌细胞壁分数(MCWF)作为治疗狗的化疗诱导的中性粒细胞缺乏症

获取原文

摘要

Chemotherapy-induced neutropenia in clinical oncology may have negative implications as it increases the risk of infection, interrupts chemotherapy protocols and requires treatment dose reduction. Currently, there is no veterinary product available for use in the prevention of chemotherapy-induced neutropenia. For many years immune response modifiers have been used for cancer treatment either alone or in conjunction with standard treatment protocols including surgery, radiation or chemotherapy. Mycobacterium Cell Wall Fraction (MCWF) is a non-specific immunomodulator derived from a non-pathogenic mycobacterium, Mycobacterium phlei which has been used for treatment of mammary tumors, osteosarcoma, transitional cell carcinoma, hemangiosarcoma and transitional venereal tumors in dogs. In addition, MCWF is currently used in Phase III clinical studies in humans for patients with bladder cancer who failed standard treatment protocols (BCG). Main purpose of our research was to demonstrate MCWF immunomodulatory potential in ameliorating the chemotherapy-induced neutropenia in dogs.
机译:在临床肿瘤学中的化疗诱导的中性粒细胞贫症可能具有负面影响,因为它增加了感染的风险,中断化疗方案并需要治疗剂量减少。目前,没有兽医产品可用于预防化疗诱导的中性粒细胞减少症。多年来,免疫反应改性剂已被单独使用或与标准治疗方案结合使用,包括手术,放射或化疗。分枝杆菌壁馏分(MCWF)是衍生自非致病性分枝杆菌的非特异性免疫调节剂,其已用于治疗乳腺癌,骨肉瘤,过渡性细胞癌,血管瘤和过渡性失育性失血性肿瘤。此外,目前MCWF目前用于人类III期临床研究,用于膀胱癌失败的标准治疗方案(BCG)。我们的研究的主要目的是在狗的改善化疗诱导的中性粒细胞率方面证明MCWF免疫调节潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号